Filing Flows › AbCellera Biologics (ABCL) › Q3 2026
AbCellera Biologics (ABCL) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
AbCellera Biologics (ABCL) reported revenue of $10.6M for the third quarter 2026 (Q3 2026), +19% from a year earlier and +163% from the quarter before. Operating margin was -501.1%, net loss $40.8M (383.1% of revenue).
AbCellera Biologics, Q3 2026: revenue $10.6M (+19% year over year), operating margin -501.1%, net loss $40.8M, operating cash flow $26.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.6M | +163% | +19% |
| Operating profit | −$53.3M | — | — |
| Net earnings | −$40.8M | — | — |
| Operating cash flow | $26.9M | +4% | — |
| Free cash flow | $25.3M | +6% | — |
What changed
Revenue was $10.6M in Q3 2026, up 19% year over year and up 163% from the previous quarter. Research fees was the largest line at 99% of revenue. Research fees added $1.7M year over year (up 20%), 103% of the total change. Licensing and royalty revenue declined 35%.
Operating costs exceeded revenue by $53.3M, an operating margin of -501.1%. Total costs fell 25% while revenue rose 19%. The fastest-growing cost line was Other operating costs (+30%). The quarter ended with a net loss of $40.8M, narrower than the previous quarter's $55.4M loss. Non-operating items added $10.5M, so the bottom line overstates operating performance.
Operating cash flow was $26.9M. Non-cash charges added back $6.8M of depreciation and amortization and $11.7M of share-based compensation. Working capital and other items added $49.2M. Capital expenditures of $1.6M left free cash flow of $25.3M.
Questions
What was AbCellera Biologics' revenue in the third quarter 2026?
AbCellera Biologics (ABCL) reported revenue of $10.6M for the third quarter 2026 (Q3 2026), +19% from a year earlier and +163% from the quarter before.
Was AbCellera Biologics profitable in the third quarter 2026?
Operating loss was $53.3M (-501.1% of revenue) and net loss $40.8M.